We report on a 4-month-old infant with delayed HIV-1 diagnosis after maternal antiretroviral therapy with long-acting injectable cabotegravir plus rilpivirine (LA-CAB/RPV) in the third trimester. Prolonged viral suppression in HIV-infected infants exposed to maternal LA-CAB/RPV may necessitate molecular testing beyond three months of age to exclude infection.
Feiterna‐Sperling et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: